AllSci News
FDA Grants Sanofi's Venglustat Breakthrough Therapy Designation for Type 3 Gaucher Disease Treatment
Sanofi (EURONEXT: SAN; NASDAQ: SNY), a Paris-headquartered biopharma company, announced that the US FDA has granted Breakthrough Therapy designation to...
Collegium acquires ADHD drug AZSTARYS from Corium Therapeutics for USD 650m plus milestones
Collegium Pharmaceutical, based in Stoughton, Massachusetts, announced a definitive agreement to acquire AZSTARYS from Corium Therapeutics Holdings for USD...
Memo Therapeutics and CSL Partner on $328M Recombinant IgG Technology Collaboration
Memo Therapeutics and CSL Forge Strategic Collaboration in Recombinant Polyclonal IgG Technology
Amlogenyx presents preclinical data for AM805 gene therapy targeting amyloid in Alzheimer's disease
Amlogenyx Reports Preclinical Data for AM805, an AAV9 Gene Therapy Designed to Degrade Amyloid in Alzheimer's Disease
Acurx Pharmaceuticals Secures US Patent for Innovative DNA Polymerase IIIC Inhibitor Technology
USPTO Grants Acurx Pharmaceuticals Patent for Innovative DNA Polymerase IIIC Inhibitor Technology
Maze Therapeutics' MZE829 shows positive phase 2 results in APOL1-mediated kidney disease trial
Maze Therapeutics (Nasdaq: MAZE), based in South San Francisco, reported topline data from its Phase II HORIZON trial of MZE829, an oral APOL1 inhibitor, in...
Crossbow Therapeutics Raises USD 77 Million in Series B to Advance Cancer Therapies
Crossbow Therapeutics, a Cambridge, Massachusetts-based biotechnology company developing TCR-mimetic antibody therapies for oncology, has closed a Series B...
ApoE4.Info and ApoE4 Alzheimer's Alliance partner on precision advocacy for APOE4 carriers
ApoE4.Info and the ApoE4 Alzheimer's Alliance, two Washington-based nonprofit organizations, announced an ApoE4 partnership on March 16, 2026, to coordinate...
FDA Issues Complete Response Letter to Disc Medicine for Bitopertin in Erythropoietic Protoporphyria Treatment
Disc Medicine, Inc. (NASDAQ: IRON) disclosed on February 13, 2026, that the U.S. Food and Drug Administration issued a Complete Response Letter for the New...
Vanda Pharmaceuticals' imsidolimab BLA accepted by FDA for generalized pustular psoriasis treatment
Washington, D.C.-based Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced on February 25, 2026, that the US FDA has accepted its Biologics License...
Teva Pharmaceutical Secures USD 400 Million Strategic Growth Capital From Blackstone Life Sciences
Teva Pharmaceutical Industries, the Israel-headquartered pharmaceutical company with U.S. operations based in Parsippany, New Jersey, has entered into a USD...
Ten63 Therapeutics Closes Strategic Financing Round Bringing Total Funding Past USD 45 Million
Ten63 Therapeutics, a Durham, North Carolina–based AI drug discovery company developing small molecules against targets long considered undruggable, has...
Atrium Therapeutics Launches With USD 270 Million as Avidity Biosciences Spinoff Targeting Cardiac RNA Medicines
San Diego-based Atrium Therapeutics has debuted as a publicly traded company (Nasdaq: RNA) with approximately USD 270 million in cash and cash equivalents...
R1 Therapeutics Launches With Oversubscribed $77.5 Million Series A for Kidney Disease Therapies
R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A...
Pfizer's atirmociclib shows progression-free survival benefit in CDK4/6 inhibitor-resistant breast cancer trial
Pfizer announced topline results from the randomized Phase II FOURLIGHT-1 trial evaluating atirmociclib in breast cancer patients whose disease had...
The AllSci Brief
Systematic R&D and deal news. Daily.